Cargando…

New emerging targets in cancer immunotherapy: the role of TIM3

Currently, the programmed death-1/programmed death ligand-1 and the cytotoxic T-lymphocyte-associated protein 4 are the two commonly targeted immune-checkpoint inhibition pathways. These drugs have significantly improved the prognosis of many cancer types. While immune-checkpoint inhibitors have rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedlaender, Alex, Addeo, Alfredo, Banna, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579568/ https://www.ncbi.nlm.nih.gov/pubmed/31275616 http://dx.doi.org/10.1136/esmoopen-2019-000497

Ejemplares similares

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Tarlatamab: a potential new option for recurrent small cell lung cancer
por: Addeo, Alfredo, et al.
Publicado: (2023)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
por: Banna, Giuseppe, et al.
Publicado: (2020)

Stepping in the right direction but still some ways to go
por: Addeo, Alfredo, et al.
Publicado: (2019)

Identifying successful biomarkers for patients with non-small-cell lung cancer
por: Friedlaender, Alex, et al.
Publicado: (2019)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy: A Promising New Standard of Care
por: Boydell, Emma, et al.
Publicado: (2023)

Reply to Authors
por: Banna, Giuseppe, et al.
Publicado: (2020)

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
por: Friedlaender, Alex, et al.
Publicado: (2019)

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review
por: Thouvenin, Laure, et al.
Publicado: (2021)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Drugging KRAS: current perspectives and state-of-art review
por: Parikh, Kaushal, et al.
Publicado: (2022)

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
por: Du, Wenwen, et al.
Publicado: (2017)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
por: Baudoux, Nathalie, et al.
Publicado: (2023)

Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
por: Parekh, Jay, et al.
Publicado: (2023)

The Role and Impact of Minimal Residual Disease in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2021)

Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
por: Mederos, Nuria, et al.
Publicado: (2020)

TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
por: Dayoub, Adam S., et al.
Publicado: (2020)

A New Generation of Vaccines in the Age of Immunotherapy
por: Addeo, Alfredo, et al.
Publicado: (2021)

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
por: Chevallier, Mathieu, et al.
Publicado: (2021)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
por: Sauer, Natalia, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

New emerging targets in cancer immunotherapy: the role of LAG3
por: Puhr, Hannah Christina, et al.
Publicado: (2019)

COVID-19 and lung cancer: risks, mechanisms and treatment interactions
por: Addeo, Alfredo, et al.
Publicado: (2020)

The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
por: Borgeaud, Maxime, et al.
Publicado: (2023)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
por: Friedlaender, Alex, et al.
Publicado: (2020)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

1393P Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immune-oncology alone or in combination with chemotherapy
por: Banna, G.L., et al.
Publicado: (2020)

VISTA: A Promising Target for Cancer Immunotherapy?
por: Tagliamento, Marco, et al.
Publicado: (2021)

New emerging targets in cancer immunotherapy: the role of VISTA
por: Tagliamento, Marco, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: the role of neoantigens
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: the role of GITR
por: Buzzatti, Giulia, et al.
Publicado: (2020)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
por: Kuang, Zhihui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_thc9rsj0thtghvlh1qncoauq67